| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
We successfully established organoids derived from biliary tract carcinoma (BTC) patients. These BTC organoids were cultured stably for over one year and closely recapitulated the histopathology, gene expression, and genetic alterations evident in the primary tumors. Gene expression profiling of the organoids and clinical data of patients revealed that SOX2, KLK6, and CPB2 could be a potential prognostic biomarker for patients with BTC. Moreover, we performed a drug screening with a compound library consisting of drugs employed clinically for their ability to suppress BTC organoids as a “drug repositioning” strategy. We discovered that the antifungal drugs amorolfine and fenticonalzole significantly suppressed the growth of BTC organoids. Antifungal drugs including amorolfine and fenticonalzole could be potentially applied for the prevention and treatment of BTC patients.
|
